[go: up one dir, main page]

MA34340B1 - Composes heteroaryles contenant de l'azote - Google Patents

Composes heteroaryles contenant de l'azote

Info

Publication number
MA34340B1
MA34340B1 MA35502A MA35502A MA34340B1 MA 34340 B1 MA34340 B1 MA 34340B1 MA 35502 A MA35502 A MA 35502A MA 35502 A MA35502 A MA 35502A MA 34340 B1 MA34340 B1 MA 34340B1
Authority
MA
Morocco
Prior art keywords
containing nitrogen
compounds containing
heteroaryl compounds
medicines
esters
Prior art date
Application number
MA35502A
Other languages
English (en)
Inventor
Konrad Bleicher
Alexander Flohr
Zbinden Katrin Groebke
Felix Gruber
Matthias Koerner
Bernd Kuhn
Jens-Uwe Peters
Sarmiento Rosa Maria Rodriguez
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MA34340B1 publication Critical patent/MA34340B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'INVENTION CONCERNE DE NOUVEAUX COMPOSÉS HÉTÉROARYLES CONTENANT DE L'AZOTE DE FORMULE (I) OÙ A1, A2, (A), R1, R2, R3, R4, R5 ET R6 SONT COMME DÉFINI DANS LA DESCRIPTION ET DANS LES REVENDICATIONS, AINSI QUE LEURS SELS PHYSIOLOGIQUEMENT ACCEPTABLES ET LEURS ESTERS. CES COMPOSÉS INHIBENT PDE10A ET PEUVENT ÊTRE UTILISÉS COMME MÉDICAMENTS.
MA35502A 2010-06-09 2011-06-06 Composes heteroaryles contenant de l'azote MA34340B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10165427 2010-06-09
PCT/EP2011/059234 WO2011154327A1 (fr) 2010-06-09 2011-06-06 Composés hétéroaryles contenant de l'azote

Publications (1)

Publication Number Publication Date
MA34340B1 true MA34340B1 (fr) 2013-06-01

Family

ID=44483879

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35502A MA34340B1 (fr) 2010-06-09 2011-06-06 Composes heteroaryles contenant de l'azote

Country Status (25)

Country Link
US (1) US8703768B2 (fr)
EP (1) EP2580207B1 (fr)
JP (1) JP5940523B2 (fr)
KR (1) KR101757959B1 (fr)
CN (1) CN102947292B (fr)
AR (1) AR081649A1 (fr)
BR (1) BR112012031343A2 (fr)
CA (1) CA2799022A1 (fr)
CL (1) CL2012003421A1 (fr)
CO (1) CO6620065A2 (fr)
CR (1) CR20120594A (fr)
EA (1) EA022075B1 (fr)
EC (1) ECSP12012330A (fr)
HK (1) HK1178900A1 (fr)
IL (1) IL223069A0 (fr)
MA (1) MA34340B1 (fr)
MX (1) MX2012013907A (fr)
NZ (1) NZ603230A (fr)
PE (1) PE20130279A1 (fr)
PH (1) PH12012502335A1 (fr)
SG (1) SG185655A1 (fr)
TW (1) TW201202221A (fr)
UA (1) UA108105C2 (fr)
WO (1) WO2011154327A1 (fr)
ZA (1) ZA201209119B (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102164896A (zh) * 2008-10-14 2011-08-24 埃科特莱茵药品有限公司 苯乙基酰胺衍生物及其杂环类似物
SG184475A1 (en) 2010-04-07 2012-11-29 Hoffmann La Roche Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
EP2675791B1 (fr) 2011-02-18 2016-02-17 Allergan, Inc. Dérivés de 6,7-dialkoxy-3-isoquinolinol substitués en tant qu'inhibiteurs de la phosphodiesterase 10 (pde10a)
AU2012314518B2 (en) 2011-09-27 2017-06-29 F. Hoffmann-La Roche Ag Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
EP2712862A1 (fr) * 2012-09-28 2014-04-02 Splicos Nouveaux composés anti-invasifs
EP2903613B1 (fr) * 2012-10-08 2017-11-22 Merck Sharp & Dohme Corp. Composés pyrazoliques utiles en tant qu'inhibiteurs d'activité d'irak4
WO2014071044A1 (fr) 2012-11-01 2014-05-08 Allergan, Inc. Dérivés de 6,7-dialcoxy-3-isoquinoline substitués à titre d'inhibiteurs de phosphodiestérase 10 (pde10a)
WO2014133046A1 (fr) 2013-02-27 2014-09-04 持田製薬株式会社 Nouveau dérivé de pyrazole
KR20160003173A (ko) * 2013-04-29 2016-01-08 에프. 호프만-라 로슈 아게 2-페닐 또는 2-헤트아릴 이미다졸[1,2-a]피리딘 유도체
GB201316600D0 (en) * 2013-09-18 2013-10-30 Redx Pharma Ltd Agricultural chemicals
US20160264536A1 (en) * 2013-10-23 2016-09-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
WO2016120355A2 (fr) * 2015-01-30 2016-08-04 Basf Se Phénylpyrimidines herbicides
RU2708066C2 (ru) * 2015-02-06 2019-12-04 Мерк Патент Гмбх Макроциклы пиридазинона в качестве ингибиторов irak-киназы и их применения
CN104610189A (zh) * 2015-02-10 2015-05-13 佛山市赛维斯医药科技有限公司 一类含环丙基脒结构sglt2/sglt1双靶点抑制剂及用途
CN104974075A (zh) * 2015-08-07 2015-10-14 新秀化学（烟台）有限公司 一种n, n-二(2,2,6,6-四甲基-4-哌啶基) -1,3-苯二甲酰胺的制备方法
KR20230156174A (ko) * 2016-07-12 2023-11-13 레볼루션 메디슨즈, 인크. 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진
CA3030087A1 (fr) 2016-07-26 2018-02-01 Basf Se Composes herbicides de pyrimidine
WO2018019767A1 (fr) 2016-07-27 2018-02-01 Basf Se Composés herbicides de pyridine
WO2018019765A1 (fr) 2016-07-27 2018-02-01 Basf Se Composés herbicides de pyrimidine
AU2017303138A1 (en) 2016-07-28 2019-01-03 Basf Se Herbicidal pyrimidine compounds
TWI820013B (zh) 2017-01-23 2023-11-01 美商銳新醫藥公司 作為別構ｓｈｐ２抑制劑之雙環化合物
EP4230623A3 (fr) 2017-01-23 2023-10-11 Revolution Medicines, Inc. Composés de pyridine en tant qu'inhibiteurs allostériques de shp2
SG11202002941WA (en) 2017-10-12 2020-04-29 Revolution Medicines Inc Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
EP3724189B1 (fr) 2017-12-15 2023-10-04 Revolution Medicines, Inc. Composés polycycliques comme inhibiteurs allosteriques de la shp2
EP3728256B1 (fr) * 2017-12-20 2024-10-02 PI Industries Ltd. Pyrazolopyridine-diamides, leur utilisation en tant qu'insecticide et leurs procédés de préparation
WO2019121352A1 (fr) 2017-12-20 2019-06-27 Basf Se Composés herbicides de pyrimidine
WO2019121374A1 (fr) 2017-12-20 2019-06-27 Basf Se Composés herbicides de pyrimidine
EA202190769A1 (ru) 2018-09-19 2021-08-18 Байер Акциенгезельшафт Гербицидно активные замещенные фенилпиримидингидразиды
PE20211693A1 (es) * 2018-11-02 2021-09-01 Merck Sharp & Dohme 2- amino-n-heteroaril-nicotinamidas como inhibidores de nav1.8
EP4052760B1 (fr) 2019-10-31 2024-03-13 FUJIFILM Corporation Dérivé de pyrazine ou sel de celui-ci et son utilisation
CN116056766A (zh) 2020-07-30 2023-05-02 富士胶片株式会社 含氮杂环化合物或其盐、其利用以及其中间体
IL302764A (en) 2020-11-13 2023-07-01 Inipharm Inc Dichlorophenol hsd17b13 inhibitors and uses thereof
EP4319872A1 (fr) * 2021-04-05 2024-02-14 Inipharm, Inc. Inhibiteurs d'hsd17b13 de type thiazole/isothiazole et leurs utilisations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9910079D0 (en) 1999-05-01 1999-06-30 Smithkline Beecham Plc Novel compounds
EP1193261A1 (fr) 2000-10-02 2002-04-03 Warner-Lambert Company Thiadiazoles et leur utilisation comme inhibiteurs de phophodiestérase-7
EP1651251A4 (fr) 2003-07-31 2008-06-18 Bayer Pharmaceuticals Corp Procedes pour traiter le diabete, et les troubles associes, au moyen d'inhibiteurs des pde10a
US7163937B2 (en) 2003-08-21 2007-01-16 Bristol-Myers Squibb Company Cyclic derivatives as modulators of chemokine receptor activity
CA2555402A1 (fr) 2004-02-12 2005-09-01 Celine Bonnefous Amides bipyridyles en tant que modulateurs du recepteur-5 metabotropique du glutamate
US20060199828A1 (en) 2005-03-04 2006-09-07 Georg Jaeschke Pyrazine-2-carboxyamide derivatives
CA2599974C (fr) 2005-03-04 2013-12-31 F. Hoffmann-La Roche Ag Derives de pyridine-2-carboxamide en tant qu'antagonistes du mglur5
AR057987A1 (es) 2005-11-24 2008-01-09 Astrazeneca Ab Compuestos agonistas de cb1 (receptor cannabinoide)
WO2008106692A1 (fr) 2007-03-01 2008-09-04 Novartis Vaccines And Diagnostics, Inc. Inhibiteurs de pim kinase et procédés de leur utilisation
WO2009026241A1 (fr) 2007-08-23 2009-02-26 Kalypsys, Inc. Modulateurs hétérocycliques de tgr5
US8470820B2 (en) * 2010-01-22 2013-06-25 Hoffman-La Roche Inc. Nitrogen-containing heteroaryl derivatives

Also Published As

Publication number Publication date
KR101757959B1 (ko) 2017-07-14
SG185655A1 (en) 2012-12-28
IL223069A0 (en) 2013-02-03
UA108105C2 (ru) 2015-03-25
CN102947292B (zh) 2015-08-19
TW201202221A (en) 2012-01-16
AR081649A1 (es) 2012-10-10
KR20130112858A (ko) 2013-10-14
ECSP12012330A (es) 2012-12-28
EP2580207B1 (fr) 2017-09-27
JP2013528193A (ja) 2013-07-08
CO6620065A2 (es) 2013-02-15
NZ603230A (en) 2013-09-27
EA201291282A1 (ru) 2013-06-28
ZA201209119B (en) 2015-05-27
EA022075B1 (ru) 2015-10-30
CR20120594A (es) 2013-01-03
MX2012013907A (es) 2012-12-17
CA2799022A1 (fr) 2011-12-15
US8703768B2 (en) 2014-04-22
BR112012031343A2 (pt) 2016-11-01
PH12012502335A1 (en) 2013-02-11
US20110306589A1 (en) 2011-12-15
EP2580207A1 (fr) 2013-04-17
JP5940523B2 (ja) 2016-06-29
WO2011154327A1 (fr) 2011-12-15
HK1178900A1 (zh) 2013-09-19
PE20130279A1 (es) 2013-03-08
CL2012003421A1 (es) 2013-07-26
CN102947292A (zh) 2013-02-27

Similar Documents

Publication Publication Date Title
MA34340B1 (fr) Composes heteroaryles contenant de l'azote
MA46452B1 (fr) Composés de benzo[b]thiophéne en tant qu'agonistes de sting
MA35753B1 (fr) Aryl-dihydropyridinones et pipéridinones en tant qu'inhibiteurs de mgat2
EA200971104A1 (ru) Производные бензимидазола
UA105229C2 (uk) Фармацевтичний склад
TW200612958A (en) Substituted imidazole derivatives
ECSP088871A (es) Derivados de triazolopirazina
MA37400B1 (fr) Composés hétérocyclyle en tant qu'inhibiteurs de mek
BRPI0818893B8 (pt) compostos de tropano, suas composições farmacêuticas, seus usos e método in vitro de inibição de hsp90 em uma célula
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
MA30162B1 (fr) Nouveaux derives de pyrrole a cycles fusionnes
CL2012000311A1 (es) Compuestos derivados que contiene ciclos con 3 atomos de nitrogeno; utiles en el tratamiento de parasitosis en animales.
MX2011013771A (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17.
MA33330B1 (fr) Quinazolines substituées comme fongicides
TN2009000287A1 (en) Cyclized derivatives as eg-5inhibitors
MX342440B (es) Derivados fluorados de aminotriazol.
TN2011000654A1 (fr) Sulfonamides heterocycliques leurs utilisations et compositions pharmaceutiques les contenant
MA29858B1 (fr) Derives de carbamoylbenzotriazole en tant qu'inhibiteurs de lipases et phospholipases
MA37886A1 (fr) Nouvelles pyridinones bicycliques
TW200800951A (en) Substituted imidazole compounds as KSP inhibitors
UA103329C2 (ru) Соли соединений-ингибиторов вич
EA201071183A1 (ru) Безводная кристаллическая форма малеата орвепитанта
MA34008B1 (fr) Composes en tant qu'antagonistes de la bradykinine b1
FR2935394B1 (fr) Microorganismes photosynthetiques enrichis en selenium organique a partir de composes seleno-hydroxyacides et leurs applications en nutrition, cosmetique et pharmacie
MA34946B1 (fr) Nouvelles benzodioxolepipérazines